Mizuho Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 40.6%

Neg 40.6% Neu 0% Pos 0%

Mizuho analyst Joseph Catanzaro downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform to Neutral and raises the price target from $110 to $135.